Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1065, pseudogene (RNU6-1065P) is a **pseudogene** locus corresponding to the U6 small nuclear RNA gene family. Pseudogenes are defective copies of functional genes; while they share sequence similarity with the parent gene, they generally lack protein-coding potential due to disabling mutations or truncations, and are not transcribed into functional products[1][2]. In some cases, pseudogenes may have regulatory roles, such as generating non-coding RNAs or acting as microRNA decoys, but there is no evidence that RNU6-1065P has such a function[1][2][3]. RNU6-1065P is not considered a therapeutic target, receptor, enzyme, transporter, or any main molecular target class. There is no known role for this pseudogene in disease, no associated therapeutic interventions, drugs, biomarkers, or safety concerns[1][2]. Additional context and clarification: - U6 small nuclear RNA genes encode a component of the spliceosome; however, pseudogene forms such as RNU6-1065P are *nonfunctional* and typically do not contribute to splicing[1][2]. - The “RNA, U6 small nuclear [number], pseudogene” naming convention refers to one of many nonfunctional sequence variants scattered throughout the genome, distinguished by their number (here, 1065), with no evidence for individual biological or clinical relevance. - There is nothing unique to suggest RNU6-1065P is a validated biological target or of therapeutic interest; its status as a pseudogene and lack of established function make it irrelevant for drug discovery[1][2][3]. - If you are seeking information on functional U6 small nuclear RNA (snRNA), you should refer to the canonical, non-pseudogene U6 snRNA genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1065, pseudogene (RNU6-1065P).